本帖最后由 老马 于 2012-1-13 21:20 编辑 + `' E, P8 B. i0 G
1 s- l/ ^7 N f; ^: M爱必妥和阿瓦斯丁的比较; k5 a- n" S2 y- Y C, \0 _
$ H0 |$ U. C, C' b4 k. V; i
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
, S8 Y- D. C/ Q0 q# s7 v' X. e, h2 j
8 k0 _$ C, b/ h" q: A2 l5 o
0 I1 f9 U8 H( c- p9 I* D O5 K
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/3 d/ l7 n' g( G
==================================================6 c+ R9 N. s" [% c
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
5 H, g/ ?4 N0 K& [" p+ ?+ S8 APatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
: z ? E: B9 p7 H9 KResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
! e! I6 D/ ^) D& S5 w
|